Compounded semaglutide can be prepared legally, and it can also be sold in ways that are not safe. The difference is the pharmacy, the prescription, and whether the patient was told this is not the Food and Drug Administration-approved product. "Compounded" is not a synonym for "the same pen, cheaper."
Ozempic and Wegovy are manufactured semaglutide products with an approved label, a tested dose, and a pen designed for that dose. A compounded preparation is made by a pharmacy for an individual prescription. It is not approved by the FDA, it is not required to match the brand pen, and a study done on the brand cannot be quoted as if it were a study of the compound.
The active ingredient people mean is semaglutide base. Versions sold as semaglutide sodium or semaglutide acetate are different substances. They have been offered as if they were the approved ingredient. A pharmacy should be able to say which form is in the vial. If it cannot, that is a reason to stop, not a detail to ignore.
Federal pharmacy law allows compounding in defined situations. One of them is a shortage of the approved drug. Another is a change an individual patient needs that the approved product cannot provide. Those are legal categories, not a marketing slogan. When the approved product is available and no patient-specific reason exists, compounding is not the default path, and a clinician has to be able to explain why a compound was chosen.
State pharmacy boards license the pharmacies that may fill these prescriptions. A website that will not name the pharmacy, the state license, or the prescriber is not in that system.
The failures that show up in warnings from regulators are practical, not theoretical:
The side effects of the GLP-1 class still apply: nausea, vomiting, diarrhea, constipation, and, less often, serious abdominal pain. A compound does not remove the class warnings, including the warning about thyroid C-cell tumors in rodents and the instruction to avoid the class in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
A careful path has all of the following. A clinician licensed where the patient is located takes a history and decides a GLP-1 medicine is appropriate. The patient is told the product is compounded and is not the approved brand. The pharmacy is licensed, named, and willing to state the ingredient and the concentration. The dose is written in a unit the patient can measure, and the prescriber reviews the first weeks rather than disappearing after checkout.
Price is not proof either way. A very low price with no clinician is a warning. A high price is not proof the pharmacy is licensed. The prescription rules that apply to any online drug, compounded or not, are in is a prescription online legal. How a brand-name Ozempic visit works is in how to get Ozempic prescribed online.
This page explains the decision. It does not approve a medication, set a dose, or replace a clinician who can see the rest of the history. Seek in-person or emergency care for severe or rapidly worsening symptoms.
The patient this page is for lives in the state where they are located.
This article is for those patients when they are deciding whether compounded semaglutide fits a visit with OhanaDoc.
The OhanaDoc visit for this topic starts with a structured intake covering symptoms, medications, allergies, and prior treatment response. A physician licensed in your state reviews whether compounded semaglutide is appropriate, whether labs are required, and whether another approach is safer. If a prescription is indicated, it is sent to a pharmacy the patient can use in the state where they are located. A franchise city's clinic does not replace that pharmacy.
A patient using OhanaDoc is evaluated by a clinician licensed in the state where they are located, not by a franchise city's clinic. Labs, when needed, can be drawn through a local partner in the state where the patient is located.